Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 3/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 2/20 | 0.34 |
| ▸ | BRAF | P15056 | 2/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.34 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.34 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.34 |
| ▸ | PBRM1 | Q86U86 | 2/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20008296 | 0.81 | SMARCA2 (0.40) | KMOOPRK1RAF1BRAFNR1I2 | |
| SCHEMBL20009213 | 0.79 | RAF1 (0.47) | RAF1BRAF | |
| SCHEMBL20010168 | 0.72 | BRAF (0.51) | RAF1BRAF | |
| SCHEMBL20008238 | 0.70 | KMO (0.37) | KMORAF1BRAF | |
| SCHEMBL20008486 | 0.68 | CNR2 (0.45) | KMOOPRK1RAF1BRAFCNR2 | |
| SCHEMBL20009643 | 0.66 | BRAF (0.43) | KMORAF1BRAFNR1I2SMARCA2 | |
| SCHEMBL20008469 | 0.65 | CNR2 (0.38) | RAF1BRAFCNR2 | |
| SCHEMBL20008331 | 0.65 | RAF1 (0.43) | RAF1BRAF | |
| SCHEMBL20008302 | 0.63 | RAF1 (0.42) | KMORAF1BRAF | |
| SCHEMBL20008328 | 0.63 | CNR2 (0.48) | RAF1BRAFCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3299367-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2018-03-28 | — | — | EP | disclosed |